Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
about
Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureA post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetesCombination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.SGLT2 Inhibitors: Benefit/Risk Balance.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
P2860
Q26752815-1BACE351-7C51-4E83-ABB2-C1A13F0F92FFQ28080114-14AB7457-5F68-4833-9C1E-2C3182DCB018Q36096350-FEEA791B-C0C7-47F2-BEB8-06745256F8B3Q36851156-3B357A92-60C0-458D-B44A-FD4F542490DAQ37561260-F8C05EBA-9585-45B8-A048-0FA7B6AAB56BQ38590229-E6B474CD-1079-4788-89AC-4C9BF232FF7FQ38619164-786B4EE8-D505-4190-9A1D-16D250C6BAAAQ38796262-745EF3C3-FA19-4209-8F6F-2071ECBFABC3Q38821464-E7EBEBA5-1DEC-4862-AB92-EF077EA1997BQ38931842-FE866C10-22C2-4488-B2CF-EC1D7EEC0A70Q39170860-A9A2C1B3-9694-4740-9AFA-3AAFAA13CF70Q39255188-5B4A8960-570F-41E2-9B99-8AA1D443F8B2Q39393777-B99358E6-9E47-433C-9838-53F1DFE99708Q40405896-7D8041E5-E885-405F-B1CA-38D1CA388E39Q47172049-38291897-BC1E-43E1-ABB6-64492FF30E0CQ52889769-FA70EE3E-679A-4919-9AEF-88527842EDF6
P2860
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Dapagliflozin lowers blood pre ...... patients with type 2 diabetes.
@en
type
label
Dapagliflozin lowers blood pre ...... patients with type 2 diabetes.
@en
prefLabel
Dapagliflozin lowers blood pre ...... patients with type 2 diabetes.
@en
P2093
P2860
P356
P1476
Dapagliflozin lowers blood pre ...... patients with type 2 diabetes.
@en
P2093
Agata Ptaszynska
C David Sjöström
Eva Johnsson
James List
Peter Johansson
P2860
P304
P356
10.1177/1479164115585298
P407
P577
2015-05-25T00:00:00Z